Affiliation:
1. The Second Affiliated Hospital of Zhejiang University School of Medicine, China
2. The Fourth Affiliated Hospital of Zhejiang University School of Medicine
3. The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital), Chinese Academy of Sciences，Hangzhou
Abstract
Abstract
Objective
To systematically evaluate the efficacy and safety of anlotinib for patients with metastatic colorectal cancer (mCRC).
Method
We searched eligible studies in PubMed, Embase, Cochrane Library, Wanfang Patent Database and China National Knowledge Infrastructure (CNKI) from database inception to September 3, 2022. A total of four random control studies were included to extract relevant data, including objective response rate (ORR), disease control rate (DCR) and the rate of adverse events. The Stata version 14.0 software was used to calculate the risk ratio (RR) with 95% confidence intervals (95% CI).
Results
This meta-analysis included 618 patients from four clinical studies. The pooled RR for ORR and DCR were 1.54 (95% CI: 1.08–2.20, P＜0.05) and 1.38 (95% CI: 1.04–1.81, P＜0.05), indicating that anlotinib administration significantly improved ORR and DCR in patients with mCRC. The pooled RR for the incidence of diarrhea was 1.64 (95% CI: 0.72–3.73, P = 0.24) and the rate of leukocytopenia was 2.32 (95% CI: 1.16–4.62, P＜0.05).
Conclusion
Anlotibin, an oral multi small-molecule receptor tyrosine kinase inhibitor, may provide clinical benefits for patients with mCRC in terms of ORR and DCR. Adverse events associated with anlotinib were tolerable.
Publisher
Research Square Platform LLC
Reference42 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;CA Cancer J Clin,2018
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022.CA Cancer J Clin2022, 72(1).
3. Clinical management of metastatic colorectal cancer in the era of precision medicine;Ciardiello F;CA Cancer J Clin,2022
4. Global patterns and trends in colorectal cancer incidence and mortality;Arnold M;Gut,2017
5. Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Robertson DJ, Rex DK. Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer.Gastroenterology2016, 150(3).